1. Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272–81.
2. Celgene Corporation. FDA grants approval of IDHIFA®, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation [media release]. 1 Aug 2017. http://www.celgene.com/ .
3. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52.
4. Celgene Corporation. IDHIFA® (enasidenib) tablets: US prescribing information. 2017. https://www.fda.gov . Accessed 30 Aug 2017.
5. US FDA. FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia [media release]. 1 Aug 2017. https://www.fda.gov .